Previous 10 | Next 10 |
Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer will present at the upcoming LD Micro Main Event Investor Conference...
Immune response data from its HOT Lung program expected early 2020 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has submitted an Investigational New Drug (IND) applicati...
Are Any Of These Penny Stocks On Your Watch List Right Now? When it comes to penny stocks to watch , timing can play a role in your strategy. Certain corporate events, disclosure filings, and even industry news can act as significant catalysts for stocks to break out. But then again, some com...
These 4 Penny Stocks Are Rallying Premarket; Can It Continue Throughout The Day? Penny stock trading is often seen as a way of getting rich quick. While penny stocks can actually bring large amounts of profits relatively quickly, it’s not as simple as it sounds. Penny stocks have ...
Cash balance anticipated to extend into 2021 Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the following updates to its clinical programs. ADXS-HOT: Cance...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies ev...
Median overall survival for ADXS-PSA in combination with KEYTRUDA ® increased to 33.6 months from previously reported 21.1 months Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherap...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal third quarter ended July 31, 2019. Key corpor...
Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer, Kenneth A. Berlin, issued an open letter to Advaxis’ stockholders. The following...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced underwritten public offering of (i) 10,650,000 sh...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...
International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...